NDM-1 is a potent class B carbapenemase that inactivates nearly all β-lactams (except aztreonam). It has spread worldwide, including in the U.S., and NDM-1–producing isolates are typically multidrug-resistant with very limited treatment options. Detecting bla_NDM-1 in a PCR panel is essential for timely identification of these high-risk, extensively drug-resistant pathogens (Luthing et al. 2020, Shakil et al. 2011).
Lutgring, J. D., Balbuena, R., Reese, N., Gilbert, S. E., Ansari, U., Bhatnagar, A., Boyd, S., Campbell, D., Cochran, J., Haynie, J., Ilutsik, J., Longo, C., Swint, S., Rasheed, J. K., Brown, A. C., & Karlsson, M. (2020). Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the United States in 2017 and 2018. Antimicrobial agents and chemotherapy, 64(9), e00499-20. https://doi.org/10.1128/AAC.00499-20
Shakil, S., Azhar, E. I., Tabrez, S., Kamal, M. A., Jabir, N. R., Abuzenadah, A. M., Damanhouri, G. A., & Alam, Q. (2011). New Delhi metallo-β-lactamase (NDM-1): an update. Journal of chemotherapy (Florence, Italy), 23(5), 263–265. https://doi.org/10.1179/joc.2011.23.5.263
